PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy

Girard N, Mornex F, Christoph DC, Fietkau R, Filippi AR, Field J, Garrido Lopez P, Mcdonald F, Peters S, Klein AB, Licour M, Garassino MC (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Geneva

DOI: 10.1093/annonc/mdz067.017

Authors with CRIS profile

Rainer Fietkau Lehrstuhl für Strahlentherapie

Involved external institutions

AstraZeneca UK Limited

United Kingdom (GB) The University of Liverpool

United Kingdom (GB) Universidad de Alcalá (UAH)

Spain (ES) Kliniken Essen-Mitte

Germany (DE) Institut Curie

France (FR) Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust

United Kingdom (GB) Policlinico San Matteo Pavia Fondazione IRCCS

Italy (IT) Hospices Civils de Lyon (CHU)

France (FR) Fondazione IRCCS: Istituto Nazionale dei Tumori

Italy (IT) Lausanne University Hospital / Centre hospitalier universitaire vaudois (CHUV)

Switzerland (CH)

How to cite

APA:

Girard, N., Mornex, F., Christoph, D.C., Fietkau, R., Filippi, A.R., Field, J.,... Garassino, M.C. (2019). PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy. In ANNALS OF ONCOLOGY. Geneva, CH: OXFORD: OXFORD UNIV PRESS.

MLA:

Girard, N., et al. "PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy." Proceedings of the European Lung Cancer Congress (ELCC), Geneva OXFORD: OXFORD UNIV PRESS, 2019.

BibTeX: Download